Veterinary Dermatology Drugs Industry Overview
The global veterinary dermatology drugs market size was valued at USD 7.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 9.3% from 2021 to 2028. The rising prevalence of skin diseases in animals, as well as high investments by market players in the segment, are the factors expected to drive the market growth. The sector has witnessed a trend of pet owners making more pet care decisions, which is expected to boost the market growth.
Gather more insights about the market drivers, restrains and growth of the Global Veterinary Dermatology Drugs Market
During the COVID-19 pandemic, most of the market players did not report any negative effect on their revenue. This was because animal health was considered an essential business, due to the high demand for animal protein. In May 2020, Jeffrey N. Simmons, CEO of Elanco stated that the industry is going into an economic slowdown. However, he also stated that its manufacturing facilities in China are actively running in full swing. The company also reported an increase of 5.1% in its therapeutics segment. On the other hand, Merck Co., Inc. reported a loss of USD 50.0 million in its animal health segment. Through this, it is evident that the overall impact of COVID-19 on Veterinary Dermatology Drugs was neutral.
An increase in the number of pet owners is driving the need for better treatment options for companion animals, which is resulting in rising health expenditure on pets. According to The American Pet Products Association, the overall spending in the U.S. pet industry increased to USD 95.7 billion in 2019 from USD 90.5 billion in 2018, and it is estimated to reach USD 99.0 billion in 2020. Moreover, in 2019-2020, about 67.0% of households in the U.S. owned a pet, which is equal to approximately 84.9 million homes. This percentage had increased by about 11% since 1988, where 56% of the households in the U.S. owned a pet.
Key players are investing to launch new products, which is also boosting the market. For instance, in May 2021, Elanco launched its first oral flea and tick product for cats. The product is called Credelio CAT (lotilaner) and it increases Elanco’s product portfolio as well as helps it to gain a competitive edge in the market.
Browse through Grand View Research's Animal Health Industry Research Reports
- Monoclonal Antibodies In Veterinary Health Market: The global monoclonal antibodies in veterinary health market size was valued at USD 0.68 billion in 2021 and is estimated to grow at a compound annual growth rate (CAGR) of 16.7% from 2022 to 2030.
- Pet Diabetes Care Market: The global pet diabetes care market size was estimated at USD 1.64 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.26% from 2022 to 2030.
Veterinary Dermatology Drugs Market Segmentation
Grand View Research has segmented the global veterinary dermatology drugs market on the basis of the animal type, route of administration, indication, distribution channel, and region:
Veterinary Dermatology Drugs Animal Type Outlook (Revenue, USD Million, 2016 - 2028)
- Companion Animal
- Livestock Animal
Veterinary Dermatology Drugs Route Of Administration Outlook (Revenue, USD Million, 2016 - 2028)
- Oral
- Topical
- Injectable
Veterinary Dermatology Drugs Indication Outlook (Revenue, USD Million, 2016 - 2028)
- Parasitic Infections
- Allergic Infections
- Others
Veterinary Dermatology Drugs Distribution Channel Outlook (Revenue, USD Million, 2016 - 2028)
- Retail
- E-Commerce
- Hospital Pharmacies
Veterinary Dermatology Drugs Regional Outlook (Revenue, USD Million, 2016 - 2028)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East Africa
Market Share Insights
- June 2021: Elanco announced an agreement to acquire Kindred Biosciences for approximately USD 440 million. With this, Elanco accelerated its expansion of the pet health market, especially advancing its presence in the fast-growing dermatology industry.
- May 2021: Elanco launched its first oral flea and tick product for cats. The product is called Credelio CAT (lotilaner) and it increases Elanco’s product portfolio as well as helps it to gain a competitive edge in the market.
- September 2020: Bioiberica launched an oral and topical range of dermatological products - Atopivet thus expanding its dermatological solutions portfolio.
Key Companies profiled:
Some of the prominent players in the global veterinary dermatology drugs market include:
- Elanco
- Vetoquinol S.A.
- Ceva
- Merck Co., Inc.
- Zoetis
- Virbac
- Bimeda, Inc.
- Vivaldis
- Bioiberica S.A.U
- Indian Immunologicals Ltd.
Order a free sample PDF of the Veterinary Dermatology Drugs Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
